Aliskiren (formerly SPP100; SPP-100; CGP-60536; CGP60536; Rasilez; Tekturna) is a direct renin inhibitor approved as an antihypertensive drug. It inhibits renin with an IC50 of 1.5 nM. Aliskiren is the first-in-class drugs called direct renin inhibitors approved for use in the treatment of essential (primary) hypertension. Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin.

纯度：≥98%

CAS：173334-57-1